Pure Encapsulations Lipid Support Complex Liver & Detoxification Lipid Support Complex supports hepatic fat metabolism with a combination of berberine and clinically studied Bergacyn®FF, a patented extract blend of bergamot citrus and Cynara cardunculus. Bergacyn®FF supports lipid metabolism in the liver, with the added benefits of supporting healthy uric acid levels, decreasing oxidative stress and supporting vascular endothelial health. This formula also provides berberine, an alkaloid that moderates lipid accumulation in liver cells in vitro. In preclinical models, berberine activates hepatic AMP kinase (AMPK) and sirutin 1 (SIRT1), which play important roles in supporting fat utilization in moderating fat synthesis in the liver. Key Benefits & Features: Supports hepatic fat metabolism Reduces oxidative stress Supports vascular health Promotes healthy uric acid levels Clinically studied BergacynFF® Ingredients Serving Size: 2 Vegetarian Capsules Amount/Serving BergaCynFF® blend 600 mg Bergamot orange (Citrus bergamia) extract (fruit) and Artichoke (Cynara cardunculus) extract (leaf) (standardized to 17% flavonoids) Berberine HCI 500 mg Other Ingredients: Vegetarian capsule (cellulose, water), hypoallergenic plant fiber (cellulose), ascorbyl palmitate, tri-magnesium citrate. Does Not Contain: Wheat, soy, dairy, eggs, artificial colors or sweeteners, coatings, shellacs, GMOs, tree nuts, peanuts, sesame, unnecessary binders, fillers or preservatives, magnesium stearate, gluten, trans fat, or hydrogenated oils. Gluten-Free, Dairy-Free, Soy-Free, Non-GMO Suggested Use As a dietary supplement, take 2 capsules daily with meals, or as directed by a health care professional. Warning: Not to be taken by pregnant or lactating women. If you have any health condition or are taking any medication, consult your health professional before use. Storage: Store in a cool, dry place. More Info. Lipid Support Complex supports hepatic fat metabolism with a combination of berberine and clinically studied BergacynFF®, a patented extract blend of bergamot citrus and Cynara cardunculus. BergacynFF® supports lipid metabolism in the liver, with the added benefits of promoting healthy uric acid levels, decreasing oxidative stress, and supporting vascular endothelial health. In a randomized, double blind, placebo-controlled clinical study involving 102 subjects, BergacynFF® (600 mg/day) for 12 weeks resulted in significant support for liver fat metabolism, assessed by CAP scores. In a randomized, double blind, placebo-controlled clinical study involving 80 subjects, BergacynFF® (600 mg/day) significantly improved serum markers of oxidative stress, with a reduction in circulating malondialdehyde (MDA) coupled with an increase in glutathione peroxidase (GPx) and superoxide dismutase (SOD) levels after 16 weeks. Supplementation also supported vascular endothelial function. Indications Ages 18 and up Patients seeking support for healthy liver fat metabolism Patients seeking support for healthy uric acid levels or oxidative stress Source Bergamot orange extract is derived from Citrus bergamia fruit Cardoon artichoke extract is derived from Cynara cardunculus leaf Ascorbyl palmitate is derived from corn dextrose fermentation and palm oil Hypoallergenic plant fiber is derived from pine cellulose Tri-magnesium citrate is derived from elemental ore and non-GMO glucose fermentation from non-GMO maize, molasses, and sugar beet or sugar cane Who Is This Supplement For? Patients seeking support for healthy liver fat metabolism Patients seeking support for healthy uric acid levels Patients aiming to reduce oxidative stress Patients who wish to maintain liver health Mechanisms of Action AMPK activation. Berberine is an alkaloid that moderates lipid accumulation in liver cells in vitro. In preclinical models, berberine activates hepatic AMP kinase (AMPK) and sirtuin 1 (SIRT1), which play important roles in supporting fat utilization in moderating fat synthesis in the liver. Hepatic lipid metabolism. The polyphenolic fraction of bergamot promotes the hepatic catabolism of fatty acids by supporting beta-oxidation, a mitochondrial pathway where fatty acids are broken down to produce energy. Preclinical data suggest that it also supports lysosomal degradation of intracellular lipids. Antioxidant effects. Clinically significant antioxidant efficacy was demonstrated in subjects receiving Bergacyn®FF, with a 24% mean reduction in circulating malondialdehyde (MDA), a biomarker of oxidative stress, in a 16-week clinical trial. Bergamot polyphenols support Nrf2 signaling, which promotes expression of antioxidant genes such as glutathione peroxidase and superoxide dismutase. Endothelial function. Significant support for vascular reactivity (assessed via EndoPAT methodology) occurred subjects supplemented with Bergacyn® FF in a 16 week study, suggesting that the extracts may influence nitric oxide release from endothelial cells. Clinical Research Highlights In a randomized, double blind, placebo-controlled clinical study involving 86 subjects (mean age 51 ± 9 years) Bergacyn®FF (600 mg/day) for 12 weeks resulted in significant support for liver fat metabolism, assessed by CAP scores. The study found that Bergacyn®FF effectively moderated liver ultrasound-based CAP scores in individuals over 50 years of age with a mean decrease of −48.2 ± 39 dB/m compared to −26.9 ± 43 dB/m in the placebo group. After adjusting for weight change, participants over 50 exhibited a 78% reduction after supplementation versus 44% in the placebo group. In a randomized, double blind, placebo-controlled clinical study involving 80 subjects (mean age 51 ± 10 years), Bergacyn®FF (600 mg/day) significantly improved serum markers of oxidative stress, with a 24% reduction in circulating malondialdehyde (MDA), a 13.8% increase in glutathione peroxidase (GPx) and a 29% increase superoxide dismutase (SOD) levels after 16 weeks. Supplementation also supported markers of liver function (gamma-glutamyltransferase and alkaline phosphatase). Additionally, favorable changes in vascular endothelial function were detected via reactive hyperemia Index, Framingham’s Hyperemia Index and Augmentation Index scores, assessed via the EndoPAT procedure. In a 6-week randomized, double blind, placebo-controlled clinical study involving 94 subjects (age 30-70), subjects receiving Bergacyn FF (600mg/day) significantlly promoted healthier serum uric acid levels (-0.1+ 0.7 mg/dL), in contrast to an elevation of 0.3 ± 0.7 mg/dL observed with placebo.1 Serum uric acid levels remained unchanged in participants with the lowest baseline measurements, while subjects with higher baseline levels (>5.4 mg/dL) experienced a significant change (−7.8%) compared to those in the lowest baseline levels (+4.9%).
